Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma

摘要: Abstract Background Prediction of outcomes in patients with renal cell carcinoma (RCC) is crucial for clinical decision-making. The limited accuracy conventional prognostic factors such as stage and grade may be increased by the use biomarkers. Objective To evaluate association serum adiponectin leptin polymorphisms receptor genes RCC histopathology prognosis. Design, setting, participants Adiponectin levels were measured preoperative samples from 131 consecutive sporadic unilateral RCC. G–2548A (rs7799039 ) gene ( LEP Gln223Arg (Q223R, A668G, rs1137101) LEPR genotyped 233 patients. Outcome measurements statistical analysis Multivariable associations RCC-specific survival analyzed using Cox models. Results limitations Median was 15.8μg/ml (interquartile range 10.0–23.1). lower distant metastases p =0.017) or histologic tumor necrosis =0.015). On multivariable adjusted effects variables Karakiewicz nomogram, each 1-μg/ml increase associated a 8% decrease hazard death (hazard ratio 0.92, 95% confidence interval 0.86–0.98; =0.007). discrimination nomogram 0.6% on inclusion adiponectin. Leptin levels, Q223R not either pathology outcomes. Limitations include retrospective study design, low numbers patients, lack standardized follow-up. Conclusions This suggests that features biologically aggressive RCC, metastasis, survival. Patient summary We assessed relationship between blood genetic changes genes. found have more tumors poorer